Revisiting the role of the Pfannenstiel incision in early-stage endometrial cancer

Abstract

Introduction: Endometrial cancer is the most common gynecologic malignancy in developed countries, and the optimal surgical approach in early-stage cases remains a subject of ongoing clinical debate.

Objective: This study aims to compare laparoscopy and Pfannenstiel incision in early-stage, low-grade endometrial cancer (EC) surgery.

Methods: A retrospective study was conducted on the records of 224 patients diagnosed with EC between April 2010 and April 2024. Only patients with stage I and grade I-II endometrioid type EC were included in the study. After excluding 94 patients with non-endometrioid histology, stage II-IV disease, grade 3 tumors, and synchronous tumors, 130 patients were included in the final analysis. Participants were categorized into two groups: Group 1 (63 patients who underwent surgery through Pfannenstiel incision) and Group 2 (67 patients who underwent laparoscopic surgery).

Results: The median overall survival (OS) was 48 months (range: 12 - 168) and the median disease-free survival (DFS) was 47 months (range: 8 - 168). During the follow-up period, 20 patients died and 8 patients experienced disease recurrence. The overall OS rate was 84.6%, and the DFS was 93.8%. When comparing groups, the OS was 85.7% in Group 1 and 83.6% in Group 2 (p=0.12). The DFS rate was significantly higher in Group 1 compared to Group 2 (96.8% vs. 91%; p=0.037).

Conclusion: This study highlights the continued relevance of staging surgery with the Pfannenstiel incision in early-stage EC patients with vaginal stenosis, morbid obesity unsuitable for trocar insertion, a history of multiple abdominal surgeries, inability to insert a manipulator, an enlarged normal uterus, or suspected pelvic adhesions.

Keywords

Endometrial cancer / Laparoscopy / Pfannenstiel incision

Funding

None.

Conflict of interest

The authors declare no competing interests.

References

[1] Crosbie EJ, Kitson SJ, McAlpine JN, Mukhopadhyay A, Powell ME, Singh N. Endometrial cancer. Lancet. 2022; 399(10333):1412-1428. doi: 10.1016/S0140-6736(22)00323-3

[2] Kalampokas E, Giannis G, Kalampokas T, et al. Current approaches to the management of patients with endometrial cancer. Cancers (Basel). 2022; 14(18):4500. doi: 10.3390/cancers14184500

[3] Bilir F, Arıoz DT, Arıkan SE, et al. Relationship between molecular markers and lymphadenectomy and lymphovascular space invasion in endometrial cancer. Arch Gynecol Obstet. 2023; 308(3):941-946. doi: 10.1007/s00404-023-07005-9

[4] Natarajan P, Delanerolle G, Dobson L, et al. Surgical treatment for endometrial cancer, hysterectomy performed via minimally invasive routes compared with open surgery: A systematic review and network meta-analysis. Cancers (Basel). 2024; 16(10):1860. doi: 10.3390/cancers16101860

[5] Patel N, Chaudhari K, Jyotsna G, Joshi JS. Surgical frontiers: A comparative review of robotics versus laparoscopy in gynecological interventions. Cureus. 2023; 15(11):e49752. doi: 10.7759/cureus.49752

[6] Giannini A, D’Oria O, Vizza E, et al. Robotic-assisted, laparoscopic, and vaginal hysterectomy in morbidly obese patients with endometrial hyperplasia and endometrial cancer. Minim Invasive Ther Allied Technol. 2024; 33:358-364. doi: 10.1080/13645706.2024.2407845

[7] Montgomery A, Van Eeden L, Boo M, et al. Does closed incision negative pressure wound therapy reduce surgical site infection in endometrial carcinoma patients undergoing laparotomy? A multicentre retrospective cohort study. Clin Exp Obstet Gynecol. 2023; 50(5):102. doi: 10.31083/j.ceog5005102

[8] Al-Majali J, Qasem M, Al-Ani A, et al. 635 transverse versus midline abdominopelvic incisions: A systematic review. Int J Gynecol Cancer. 2021; 31(Suppl 3):A36-A36. doi: 10.1136/ijgc-2021-ESGO.52

[9] Ayhan A, Dursun P, Gultekin M, Esin S. Pfannenstiel vs. Midline incision for early stage endometrial carcinoma. Int J Gynecol Obstet. 2006; 93(1):67-69. doi: 10.1016/j.ijgo.2005.12.029

[10] Rady HA, Mohammed NE, Ragab MH. Lower midline versus pfannenstiel incision in pelvic lymphadenectomy in endometrial cancer. Indian J Gynecol Oncol. 2019;17:36.

[11] Tzenios N, Chahine M, Tazanios M. Obesity and endometrial cancer: The role insulin resistance and adipokines. Special J Med Acad Other Life Sci. 2023; 1(2). doi: 10.58676/sjmas.v1i2.12

[12] Skolnik E, Miazga E, Zakhari A, Cai E, Ziegler C, Murji A. Beyond the pfannenstiel: Minimally invasive laparotomy incisions for maximum exposure. J Obstet Gynaecol Can. 2021; 43(3):368. doi: 10.1016/j.jogc.2020.10.013

[13] Vaezi M, Zarei R, Azizi H. Comparison of maylard and cherney incisions’ outcomes in hysterectomy surgery for benign indications: A double-blind randomized controlled trial. Eur J Med Res. 2025; 30(1):56. doi: 10.1186/s40001-025-02311-1

[14] Güven E, Dura MC, Aktürk H, Güraslan H. Safety of laparoscopic entry points in patients with a history of abdominal surgery: A research article. Cureus. 2023; 15(10):e47244. doi: 10.7759/cureus.47244

[15] Matsuo K, Sood AK, Gershenson DM. Management of early-stage ovarian cancer. In: Surgery for Ovarian Cancer. United States: CRC Press; 2022. p. 60-92.

[16] Polen-De C, Bakkum-Gamez J, Langstraat C. Route of hysterectomy for benign disease: Abdominal hysterectomy. J Gynecol Surg. 2021; 37(2):116-121. doi: 10.1089/gyn.2021.0002

[17] Abdelazim I, AbuFaza M. Pfannenstiel incision for surgical excision of a huge pelvi-abdominal cystadenoma: A case report. Prz Menopauzalny. 2021; 20(2):99-102. doi: 10.5114/pm.2021.106469

[18] Habib AS, Wahl K, Gu J, Gan TJ, Adenosine Study Group. Comparison of postoperative pain outcomes after vertical or Pfannenstiel incision for major gynecologic surgery. Curr Med Res Opin. 2009; 25(6):1529-1534. doi: 10.1185/03007990902959168

[19] Lewin SN, Herzog TJ, Medel NI, et al. Comparative performance of the 2009 international federation of gynecology and obstetrics’ staging system for uterine corpus cancer. Obstet Gynecol. 2010; 116(5):1141-1149. doi: 10.1097/AOG.0b013e3181f39849

[20] Bogani G, Ray-Coquard I, Concin N, et al. Clear cell carcinoma of the endometrium. Gynecol Oncol. 2022; 164(3):658-666. doi: 10.1016/j.ygyno.2022.01.012

[21] Hasson HM. A modified instrument and method for laparoscopy. Am J Obstet Gynecol. 1971; 110:886-887. doi: 10.1016/0002-9378(71)90593-x

[22] Fathi A, Saleh MM, Shetiwy M, et al. Operative outcomes of single-incision laparoscopic hysterectomy vs conventional laparoscopic total hysterectomy: A prospective randomized controlled study. Surg Innov. 2022; 29(5):590-599. doi: 10.1177/15533506211041892

[23] McCurdy RJ, Harding S, Felder L, Beáta A, Schnatz P, Berghella V. Cohen vs Pfannenstiel cesarean skin incision for body mass index ≥35 kg/m2: A randomized controlled trial. Am J Obstet Gynecol MFM. 2024; 6(12):101528. doi: 10.1016/j.ajogmf.2024.101528

[24] Januszek SM, Wita-Popow B, Kluz M, et al. Risk factors for surgical treatment of endometrial cancer using traditional and laparoscopic methods. J Clin Med. 2021; 10(3):429. doi: 10.3390/jcm10030429

[25] Pecorelli S. Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int J Gynaecol Obstet. 2009; 105:103-104. doi: 10.1016/j.ijgo.2009.02.012

[26] Berek JS, Matias-Guiu X, Creutzberg C, et al. FIGO staging of endometrial cancer: 2023. Int J Gynecol Obstet. 2023; 162(2):383-394. doi: 10.1002/ijgo.14923

[27] Pergialiotis V, Panagiotopoulos M, Koutras A, et al. The impact of positive peritoneal cytology on the survival rates of early-stage-disease endometrial cancer patients: Systematic review and meta-analysis. Medicina. 2024; 60(5):733.doi: 10.3390/medicina60050733

[28] Takenaka M, Kamii M, Iida Y, et al. Re-thinking the prognostic significance of positive peritoneal cytology in endometrial cancer. Gynecol Oncol. 2021; 161(1):135-142. doi: 10.1016/j.ygyno.2021.01.007

[29] Padilla-Iserte P, Lago V, Tauste C, et al. Impact of uterine manipulator on oncological outcome in endometrial cancer surgery. Am J Obstet Gynecol. 2021; 224:65-e1.e11. doi: 10.1016/j.ajog.2020.07.025

[30] Machida H, Hom MS, Adams CL, et al. Intrauterine manipulator use during minimally invasive hysterectomy and risk of lymphovascular space invasion in endometrial cancer. Int J Gynecol Cancer. 2018; 28(2):208-219. doi: 10.1097/IGC.0000000000001181

[31] Matsuo K, Klar M, Nusbaum DJ, et al. Utilization and outcomes of sentinel lymph node biopsy for early endometrial cancer. Obstet Gynecol. 2022; 139(5):809-820. doi: 10.1097/AOG.0000000000004733

[32] Raffone A, Fanfani F, Raimondo D, et al. Predictive factors of sentinel lymph node failed mapping in endometrial carcinoma patients: A systematic review and meta-analysis. Int J Gynecol Cancer. 2023; 33(6):853-859. doi: 10.1136/ijgc-2022-004014

[33] Baiocchi G, Andrade CEMC, Ribeiro R, et al. Sentinel lymph node mapping versus sentinel lymph node mapping with systematic lymphadenectomy in endometrial cancer: An open-label, non-inferiority, randomized trial (ALICE trial). Int J Gynecol Cancer. 2022; 32(5):676-679. doi: 10.1136/ijgc-2022-003378

[34] Zammarrelli WA 3rd., Afonso AM, Broach V, et al. Sentinel lymph node biopsy in patients with endometrial cancer and an indocyanine green or iodinated contrast reaction-a proposed management algorithm. Gynecol Oncol. 2021; 162(2):262-267. doi: 10.1016/j.ygyno.2021.05.009

[35] Segarra B, Meyer LA, Malpica A, Bhosale P. Endometrial cancer recurrence at multiple port sites. Int J Gynecol Cancer. 2020; 30(6):893-896. doi: 10.1136/ijgc-2020-001327

[36] Frumovitz M, Obermair A, Coleman RL, et al. Quality of life in patients with cervical cancer after open versus minimally invasive radical hysterectomy (LACC): A secondary outcome of a multicentre, randomised, open-label, phase 3, non-inferiority trial. Lancet Oncol. 2020; 21(6):851-860. doi: 10.1016/S1470-2045(20)30081-4

[37] Gultekin M, Dundar S, Kucukyildiz I, et al. Survival of gynecological cancers in Turkey: Where are we at? J Gynecol Oncol. 2017; 28(6):e85. doi: 10.3802/jgo.2017.28.e85

[38] Kurosu H, Todo Y, Yamada R, et al. A BMI-category distribution pattern of intrinsic and treatment-related prognostic factors in endometrial cancer. Jpn J Clin Oncol. 2021; 51(5):722-727. doi: 10.1093/jjco/hyaa274

[39] Stuart GC, Kitchener H, Bacon M, et al. 2010 gynecologic cancer intergroup (GCIG) consensus statement on clinical trials in ovarian cancer: Report from the fourth ovarian cancer consensus conference. Int J Gynecol Cancer. 2011; 21:750-755. doi: 10.1097/IGC.0b013e31821b2568

[40] Alouini S, Bakri Y. Para-aortic lymphadenectomy in ovarian, endometrial, gastric, and bladder cancers: A systematic review of randomized controlled trials. Cancers (Basel). 2024; 16(19):3394. doi: 10.3390/cancers16193394

[41] Ronsini C, Iavarone I, Vastarella MG, et al. SIR-EN-new biomarker for identifying patients at risk of endometrial carcinoma in abnormal uterine bleeding at menopause. Cancers (Basel). 2024; 16(21):3567. doi: 10.3390/cancers16213567

[42] Lubiński J, Lener MR, Marciniak W, et al. Serum essential elements and survival after cancer diagnosis. Nutrients. 2023; 15(11):2611. doi: 10.3390/nu15112611